UniProt Q9HAZ1 · PDB · AlphaFold · Substrate: MBP · Clone: full-lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Brigatinib | 97.2% | 2.8% | 82.96 | 0.513 |
| 2 | Abemaciclib | 96.5% | 3.5% | 91.48 | 0.563 |
| 3 | Sunitinib | 89.5% | 10.5% | 91.73 | 0.524 |
| 4 | Gilteritinib | 89.2% | 10.8% | 88.97 | 0.506 |
| 5 | Midostaurin | 87.1% | 12.9% | 78.64 | 0.500 |
| 6 | Palbociclib | 85.9% | 14.1% | 98.75 | 0.673 |
| 7 | Alectinib | 82.8% | 17.2% | 95.49 | 0.651 |
| 8 | Pacritinib | 80.6% | 19.4% | 88.64 | 0.452 |
| 9 | Defactinib | 78.3% | 21.7% | 92.68 | 0.450 |
| 10 | Nilotinib | 77.6% | 22.4% | 96.49 | 0.765 |
| 11 | Ceritinib | 74.0% | 25.9% | 95.44 | 0.618 |
| 12 | Baricitinib | 68.4% | 31.6% | 97.99 | 0.616 |
| 13 | Capivasertib | 65.8% | 34.3% | 96.48 | 0.644 |
| 14 | Avapritinib | 59.8% | 40.2% | 97.73 | 0.644 |
| 15 | Bosutinib | 57.4% | 42.6% | 87.22 | 0.555 |
| 16 | Ruxolitinib | 43.3% | 56.7% | 98.25 | 0.592 |
| 17 | Nintedanib | 36.4% | 63.6% | 90.23 | 0.608 |
| 18 | Alpelisib | 30.7% | 69.3% | 97.22 | 0.720 |
| 19 | Abrocitinib | 28.8% | 71.2% | 99.50 | 0.581 |
| 20 | Selpercatinib | 26.9% | 73.1% | 96.72 | 0.635 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 3.58
- Epithelial log2(TPM+1): 3.54
- Fold change: 0.04
- Status: No significant change
High-confidence drugs
- Palbociclib — inh 85.9% · KISS 37.86
- Abemaciclib — inh 96.5% · KISS 33.58
- Brigatinib — inh 97.2% · KISS 28.90
Selectivity landscape vs inhibition on CLK4
Each point is one of the 92 approved drugs; color = inhibition % on CLK4.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…